PMID- 18672190
OWN - NLM
STAT- MEDLINE
DCOM- 20090224
LR  - 20220330
IS  - 1532-8414 (Electronic)
IS  - 1071-9164 (Linking)
VI  - 14
IP  - 6
DP  - 2008 Aug
TI  - Pioglitazone and heart failure: results from a controlled study in patients with 
      type 2 diabetes mellitus and systolic dysfunction.
PG  - 445-52
LID - 10.1016/j.cardfail.2008.02.007 [doi]
AB  - BACKGROUND: Thiazolidinediones are associated with fluid retention, often 
      interpreted as worsening cardiac function, limiting their use in patients with 
      heart failure (HF). We compared the effects of pioglitazone and glyburide on 
      cardiac function in patients with type 2 diabetes, systolic dysfunction, and New 
      York Heart Association (NYHA) functional Class II/III HF. METHODS AND RESULTS: 
      Participants received pioglitazone or glyburide (+/-insulin) for 6 months in this 
      double-blind, randomized, multicenter study. The primary end point was time to 
      HF, a composite of cardiovascular mortality and hospitalization or emergency room 
      (ER) visit for HF. Secondary endpoints included echocardiographic and functional 
      classification assessments. An earlier time to onset and higher incidence of the 
      primary endpoint was noted with pioglitazone (13%) versus glyburide (8%) (P = 
      .024). Hospitalization or ER visit occurred in 30 pioglitazone and 15 glyburide 
      participants, 19 and 12 of whom, respectively, continued treatment. Cardiac 
      mortality (5 versus 6 participants, respectively) and cardiac function, as 
      measured by change in ventricular mass index (P = .959), ejection fraction (P = 
      .413), or fractional shortening (P = .280), were similar between treatments. 
      CONCLUSIONS: Pioglitazone was associated with a higher incidence of 
      hospitalization for HF without an increase in cardiovascular mortality or 
      worsening cardiac function (by echocardiography).
FAU - Giles, Thomas D
AU  - Giles TD
AD  - Tulane University School of Medicine, New Orleans, Louisiana, USA.
FAU - Miller, Alan B
AU  - Miller AB
FAU - Elkayam, Uri
AU  - Elkayam U
FAU - Bhattacharya, Mondira
AU  - Bhattacharya M
FAU - Perez, Alfonso
AU  - Perez A
LA  - eng
SI  - ClinicalTrials.gov/NCT00521820
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080527
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
RN  - 0 (Thiazolidinediones)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
CIN - J Card Fail. 2008 Aug;14(6):453-5. PMID: 18672191
MH  - Aged
MH  - Diabetes Mellitus, Type 2/*complications/*drug therapy/mortality
MH  - Double-Blind Method
MH  - Endpoint Determination/trends
MH  - Female
MH  - Heart Failure, Systolic/*chemically induced/*complications/mortality
MH  - Hospitalization/trends
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone
MH  - Prospective Studies
MH  - Thiazolidinediones/*adverse effects
EDAT- 2008/08/02 09:00
MHDA- 2009/02/25 09:00
CRDT- 2008/08/02 09:00
PHST- 2007/08/27 00:00 [received]
PHST- 2008/01/22 00:00 [revised]
PHST- 2008/02/05 00:00 [accepted]
PHST- 2008/08/02 09:00 [pubmed]
PHST- 2009/02/25 09:00 [medline]
PHST- 2008/08/02 09:00 [entrez]
AID - S1071-9164(08)00060-2 [pii]
AID - 10.1016/j.cardfail.2008.02.007 [doi]
PST - ppublish
SO  - J Card Fail. 2008 Aug;14(6):445-52. doi: 10.1016/j.cardfail.2008.02.007. Epub 
      2008 May 27.